16 completed, 5 unknown, 4 terminated, 2 withdrawn. 30 Phase 2, 8 Phase 3, 6 Phase 1.
Follow 0.9% Normal saline: new trials by email Literature Review of 0.9% Normal saline trials Research Report on 0.9% Normal saline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. Semaglutide, Placebo - Type 1 Diabetes, Overweight , Obesity | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 40 | 2026-10-13 | 2026-10-23 |
| A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA） NCR100, 0.9% Normal saline - Knee Osteoarthritis | Phase 1 / Phase 2 | Not yet recruiting | Nuwacell Biotechnologies Co., Ltd. | 162 | 2025-02-20 | 2024-12-18 |
| Effect of Fluid Resuscitation on Lactate in Traumatic Injury Patients 3% hypertonic Saline, Ringer's lactated solution, 0.9% Normal saline - Fluid Resuscitation | Phase 1 / Phase 2 | Unknown | Assiut University | 150 | 2024-08-01 | 2024-04-17 |
| Effect of Topical Insulin on Healing Rate of Pemphigus Lesions insulin glargine, human insulin, 0.9% Normal Saline - Pemphigus Vulgaris, Skin Erosion | Phase 2 | Completed | Alexandria University | 20 | 2024-06-22 | 2026-03-10 |
| Angiotensin II in Liver Transplantation Angiotensin II, Saline - Liver Transplant; Complications, Vasoplegia | Phase 2 / Phase 3 | Active not recruiting | University of California, San Francisco | 50 | 2022-06-28 | 2026-03-20 |
| Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section Granisetron Hydrochloride, 0.9% normal saline - Granisetron | Phase 2 / Phase 3 | Unknown | Assiut University | 102 | 2022-04-01 | 2022-04-06 |
| Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia hzVSF-v13, Placebo (Normal saline solution) - COVID-19 | Phase 2 | Terminated | ImmuneMed, Inc. | 1 | 2021-03-18 | 2024-02-15 |
| Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment - COVID-19 | Phase 2 | Terminated | Grifols Therapeutics LLC | 57 | 2021-01-29 | 2023-03-22 |
| Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia hzVSF-v13, Placebo (Normal saline solution) - COVID-19 | Phase 2 | Completed | ImmuneMed, Inc. | 63 | 2020-12-17 | 2024-02-15 |
| Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia hzVSF-v13, Placebo (Normal saline solution) - COVID-19 | Phase 2 | Completed | ImmuneMed, Inc. | 115 | 2020-12-11 | 2021-12-01 |
| Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Ivermectin Injectable Solution, Injectable Placebo, Zinc - Coronavirus Infection, COVID | Phase 1 / Phase 2 | Unknown | Sohaib Ashraf | 180 | 2020-11-14 | 2021-02-17 |
| Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure Dociparstat sodium, Placebo - Coronavirus Disease 2019 (COVID-19), Acute Lung Injury | Phase 2 / Phase 3 | Terminated | Jazz Pharmaceuticals | 27 | 2020-07-08 | 2022-08-30 |
| Intravenous Lidocaine on Chronic Pain in Patients Undergoing Hepatectomy Lidocaine Hydrochloride, Injectable, 0.9% normal saline - Postoperative Chronic Pain | Phase 2 | Unknown | West China Hospital | 260 | 2020-02-27 | 2024-04-19 |
| Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: A Pilot and Feasibility Study Tranexamic Acid, Placebo - Brain Injuries, Wounds and Injuries | Phase 2 | Completed | Daniel Nishijima, MD, MAS | 31 | 2019-03-04 | 2021-09-05 |
| To Evaluate the Effect of Wound Infiltration With Bupivacaine for Post-operative Pain Relief After Laparoscopic Cholecystectomy Bupivacaine, 0.9% normal saline - Post-operative Pain | Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 58 | 2019-01-01 | 2020-06-01 |
| Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma Tranexamic Acid, 0.9% Normal Saline - Effect of Drugs, Adverse Effects of Medical Drugs | Phase 2 / Phase 3 | Completed | Jinnah Postgraduate Medical Centre | 30 | 2018-09-01 | 2019-12-17 |
| Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection GEN-003, Matrix-M2, 0.9% normal saline - Genital Herpes, HSV-2 Infection | Phase 2 | Terminated | Genocea Biosciences, Inc. | 33 | 2017-05-24 | 2019-02-19 |
| The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Pharmaceutical composition containing botulinum toxin, 0.9% normal saline, Coronary artery bypass grafting - Atrial Fibrillation, Ischemic Heart Disease | Phase 2 | Unknown | Meshalkin Research Institute of Pathology of Circulation | 180 | 2016-09-01 | 2016-12-05 |
| Evaluating New Formulation of Therapeutic HSV-2 Vaccine Matrix-M2, GEN-003, Placebo - Genital Herpes Simplex Type 2 | Phase 2 | Completed | Genocea Biosciences, Inc. | 131 | 2015-11-01 | 2018-05-22 |
| Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Reslizumab, Placebo - Severe Persistent Asthma, Eosinophilic Bronchitis | Phase 2 / Phase 3 | Completed | McMaster University | 10 | 2015-10-01 | 2018-04-04 |
Showing 20 of 30. Sign in to see all of them.
COVID-19 (6) · Clostridium Infections (3) · Hemorrhage (3) · Pain, Postoperative (3) · Asthma (2) · Diarrhea (2) · Herpes Genitalis (2) · Herpes Simplex (2) · Wounds and Injuries (2) · Acute Kidney Injury (1) · Acute Lung Injury (1) · Atherosclerosis (1) · Atrial Fibrillation (1) · Brain Injuries (1) · Bronchitis (1)
ImmuneMed, Inc. (3) · Sanofi Pasteur, a Sanofi Company (3) · Assiut University (2) · Genocea Biosciences, Inc. (2) · McMaster University (2) · Alexandria University (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Boston Children's Hospital (1) · Daniel Nishijima, MD, MAS (1) · Diffusion Pharmaceuticals Inc (1) · Grifols Therapeutics LLC (1) · Jawaharlal Institute of Postgraduate Medical Education & Research (1) · Jazz Pharmaceuticals (1) · Jinnah Postgraduate Medical Centre (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1)
United States (12) · Canada (3) · Egypt (2) · Pakistan (2) · Russia (2) · South Korea (2) · Bangladesh (1) · Brazil (1) · Chile (1) · China (1) · Colombia (1) · India (1) · Indonesia (1) · Italy (1) · Japan (1)
Parameswaran Nair, MD, PhD (2) · Bruce D Spiess, MD, FAHA (1) · Carmen I Farid, MB BCh, MD (1) · Catherine Lemiere, MD (1) · Chunling Jiang, PhD (1) · Daniel K Nishijima, MD, MAS (1) · Davide Sonnino, phD (1) · Delbert Dorscheid, MD (1) · Dong-Ju Choi, MD, PhD (1) · Jennifer H Aldrink, MD (1) · Louis-Philippe Boulet, MD (1) · Melissa-Rosina Pasqua, MD, PhD (1) · Michael P Bokoch, M.D., Ph.D. (1) · Moneeb Ashraf, MBBS (1)
PMID 21364458, PMID 22003000, PMID 23371895, PMID 23506972, PMID 25184917, PMID 26220293, PMID 27013431, PMID 28183347, PMID 28726212, PMID 28915080, PMID 29116880, PMID 30376893, PMID 30988677, PMID 31103365, PMID 31271691, PMID 31299040, PMID 31537446, PMID 32278572, PMID 34488858, PMID 35244208, PMID 35977357, PMID 37984940
2008 (1)